🚀 VC round data is live in beta, check it out!
Assertio Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Assertio Therapeutics and similar public comparables like Cardiff Oncology, XSpray Pharma, Genelux, PepGen and more.
Assertio Therapeutics Overview
About Assertio Therapeutics
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Founded
1995
HQ
Employees
58
Website
Sectors
Financials (LTM)
EV
$93M
Assertio Therapeutics Financials
Assertio Therapeutics reported last 12-month revenue of $115M and EBITDA of $22M.
In the same LTM period, Assertio Therapeutics generated $81M in gross profit, $22M in EBITDA, and had net loss of ($24M).
Revenue (LTM)
Assertio Therapeutics P&L
In the most recent fiscal year, Assertio Therapeutics reported revenue of $119M and EBITDA of $23M.
Assertio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $115M | XXX | $119M | XXX | XXX | XXX |
| Gross Profit | $81M | XXX | $83M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $22M | XXX | $23M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | (14%) | XXX | (15%) | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($30M) | XXX | XXX | XXX |
| Net Margin | (21%) | XXX | (26%) | XXX | XXX | XXX |
| Net Debt | — | — | $29M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Assertio Therapeutics Stock Performance
Assertio Therapeutics has current market cap of $116M, and enterprise value of $93M.
Market Cap Evolution
Assertio Therapeutics' stock price is $18.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93M | $116M | -2.4% | XXX | XXX | XXX | $-4.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAssertio Therapeutics Valuation Multiples
Assertio Therapeutics trades at 0.8x EV/Revenue multiple, and 4.2x EV/EBITDA.
EV / Revenue (LTM)
Assertio Therapeutics Financial Valuation Multiples
As of April 11, 2026, Assertio Therapeutics has market cap of $116M and EV of $93M.
Equity research analysts estimate Assertio Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Assertio Therapeutics has a P/E ratio of (4.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $116M | XXX | $116M | XXX | XXX | XXX |
| EV (current) | $93M | XXX | $93M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 4.2x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBIT | (5.9x) | XXX | (5.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| P/E | (4.8x) | XXX | (3.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Assertio Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Assertio Therapeutics Margins & Growth Rates
Assertio Therapeutics' revenue in the last 12 month declined by (7%).
Assertio Therapeutics' revenue per employee in the last FY averaged $2.0M, while opex per employee averaged $1.7M for the same period.
Assertio Therapeutics' rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Assertio Therapeutics' rule of X is (12%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Assertio Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (7%) | XXX | (13%) | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | (9%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 7% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (12%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Assertio Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cardiff Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XSpray Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Genelux | XXX | XXX | XXX | XXX | XXX | XXX |
| PepGen | XXX | XXX | XXX | XXX | XXX | XXX |
| ProMIS Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Assertio Therapeutics M&A Activity
Assertio Therapeutics acquired XXX companies to date.
Last acquisition by Assertio Therapeutics was on XXXXXXXX, XXXXX. Assertio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Assertio Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAssertio Therapeutics Investment Activity
Assertio Therapeutics invested in XXX companies to date.
Assertio Therapeutics made its latest investment on XXXXXXXX, XXXXX. Assertio Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Assertio Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Assertio Therapeutics
| When was Assertio Therapeutics founded? | Assertio Therapeutics was founded in 1995. |
| Where is Assertio Therapeutics headquartered? | Assertio Therapeutics is headquartered in United States. |
| How many employees does Assertio Therapeutics have? | As of today, Assertio Therapeutics has over 58 employees. |
| Who is the CEO of Assertio Therapeutics? | Assertio Therapeutics' CEO is Mark L. Reisenauer. |
| Is Assertio Therapeutics publicly listed? | Yes, Assertio Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Assertio Therapeutics? | Assertio Therapeutics trades under ASRT ticker. |
| When did Assertio Therapeutics go public? | Assertio Therapeutics went public in 1997. |
| Who are competitors of Assertio Therapeutics? | Assertio Therapeutics main competitors are Cardiff Oncology, XSpray Pharma, Genelux, PepGen. |
| What is the current market cap of Assertio Therapeutics? | Assertio Therapeutics' current market cap is $116M. |
| What is the current revenue of Assertio Therapeutics? | Assertio Therapeutics' last 12 months revenue is $115M. |
| What is the current revenue growth of Assertio Therapeutics? | Assertio Therapeutics revenue growth (NTM/LTM) is (7%). |
| What is the current EV/Revenue multiple of Assertio Therapeutics? | Current revenue multiple of Assertio Therapeutics is 0.8x. |
| Is Assertio Therapeutics profitable? | Yes, Assertio Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Assertio Therapeutics? | Assertio Therapeutics' last 12 months EBITDA is $22M. |
| What is Assertio Therapeutics' EBITDA margin? | Assertio Therapeutics' last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Assertio Therapeutics? | Current EBITDA multiple of Assertio Therapeutics is 4.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.